+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Castration-resistant Prostate Cancer Drugs Market by Therapeutic Mechanism, Drug Classification, Clinical Development Stage, Administration Route, Safety and Efficacy, Patient Profile, Molecular and Chemical Structure, Market Adoption and Reimbursement - Global Forecast to 2030- Product Image
Castration-resistant Prostate Cancer Drugs Market by Therapeutic Mechanism, Drug Classification, Clinical Development Stage, Administration Route, Safety and Efficacy, Patient Profile, Molecular and Chemical Structure, Market Adoption and Reimbursement - Global Forecast to 2030- Product Image
Sale

Castration-resistant Prostate Cancer Drugs Market by Therapeutic Mechanism, Drug Classification, Clinical Development Stage, Administration Route, Safety and Efficacy, Patient Profile, Molecular and Chemical Structure, Market Adoption and Reimbursement - Global Forecast to 2030

  • PDF Icon

    Report

  • 189 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6161039
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
Prostate cancer that progresses despite the suppression of androgen signaling epitomizes one of the most challenging scenarios in modern oncology. Castration-resistant prostate cancer arises when tumor cells circumvent androgen deprivation, driving continued proliferation and metastasis even at castrate testosterone levels. This transition marks a critical inflection point in the disease trajectory, as options beyond hormonal manipulation become essential to extend survival and preserve quality of life. Despite strides in early detection and localized interventions, the therapeutic landscape for advanced disease remains fragmented and clinically complex. In response, researchers and pharmaceutical developers have pursued a spectrum of novel modalities, from next-generation androgen receptor antagonists and Cyp17 inhibitors to immunomodulators and targeted signal transduction disruptors. Moreover, the integration of digital health platforms and real-world evidence is progressively informing patient selection and outcome measurement. This executive summary synthesizes the latest developments across regulatory, economic, and technological domains. It highlights shifting therapy paradigms, the forthcoming impact of US trade measures, granular market segmentation, regional adoption patterns, and the competitive positioning of key stakeholders. By distilling these elements, decision-makers can navigate emerging opportunities and devise strategies that align clinical innovation with sustainable market access.

Transformative Shifts Redefining Therapy Development and Patient Care

Over the past decade, the castration-resistant prostate cancer arena has witnessed transformative shifts that redefine both therapeutic development and patient care pathways. Initially dominated by sequential hormonal therapies, the field has expanded to embrace multipronged strategies, coupling androgen receptor antagonism with novel mechanisms such as immunomodulation and targeted signal transduction disruption. Concurrently, the integration of real-world evidence and precision oncology has enabled more nuanced patient stratification, ensuring that high-risk subpopulations receive tailored regimens. Advances in biomarker discovery-ranging from circulating tumor DNA profiling to tissue-based molecular assays-have accelerated the selection of appropriate candidates for emerging therapies. Furthermore, combination approaches that blend immunotherapy with hormone blockade or chemotherapy are yielding promising efficacy signals, underscoring the value of synergistic modalities. Digital health tools now support remote monitoring of treatment responses and adverse events, enhancing patient engagement and adherence. Collectively, these paradigm shifts are catalyzing a more dynamic ecosystem in which data-driven decision-making, regulatory agility, and cross-sector collaboration converge to accelerate the path from bench to bedside.

Cumulative Impact of United States Tariffs 2025 on Drug Supply and Costs

The implementation of new United States tariffs slated for 2025 presents a critical economic headwind for castration-resistant prostate cancer drug supply chains and pricing structures. As the US administration broadens tariff coverage to include key active pharmaceutical ingredients and specialized excipients, manufacturers face increased import costs that cascade through formulation, packaging, and distribution layers. Pharmaceutical supply networks must adapt quickly to mitigate cost inflation, with potential strategies including nearshore production of intermediates, development of redundant sourcing agreements, and investment in domestic manufacturing capacity. In parallel, payers and health systems may scrutinize price adjustments more rigorously, heightening the importance of demonstrating compelling clinical and pharmacoeconomic value. Regulatory pathways such as accelerated approval or priority review could help buffer the impact by shortening time to market and enhancing product access during early commercial launches. Moreover, firms that proactively engage with policymakers and industry consortia to advocate for tariff exemptions on critical oncology inputs may secure more stable tariff frameworks. In this evolving policy landscape, agility in procurement, manufacturing resilience, and value-based contracting will be essential to preserve patient access and maintain margins.

Key Insights from Market Segmentation across Mechanisms, Classifications, and Development Stages

A multifaceted segmentation framework illuminates the diverse axes along which the castration-resistant prostate cancer market unfolds. From a therapeutic mechanism perspective, the landscape encompasses established androgen receptor antagonists, Cyp17 inhibitors, and a burgeoning class of novel mechanism agents that includes immunomodulators and signal transduction disruptors. In terms of drug classification, the portfolio extends across chemotherapy agents, hormonal therapy agents, immunotherapy agents, and targeted therapy agents, each delivering distinct efficacy and safety profiles. Evaluating clinical development stages reveals a continuum from preclinical testing through to marketed products, with phase I, II, and III trials-both completed and ongoing-offering insights into emerging pipelines. Administration routes vary from intravenous and oral to subcutaneous and transdermal modalities, shaping patient convenience and adherence. Safety and efficacy segmentation further refines the view by examining adverse effect profiles-including mild, moderate, and severe reactions-alongside drug interaction risks and overall tolerance levels. Patient profile criteria such as age range, comorbidities, genetic markers, and performance status guide treatment personalization. Finally, molecular and chemical structure analysis covers biomarker associations, chemical properties, molecular targets, and resistance mechanisms, while market adoption factors-including adoption rate, cost effectiveness, insurance coverage, and reimbursement policies-determine real-world uptake and commercial viability.

Critical Regional Dynamics Shaping Market Penetration and Access

Regional dynamics exert a profound influence on the commercial trajectory of castration-resistant prostate cancer therapies. In the Americas, the United States and Canada drive innovation through robust regulatory frameworks and high adoption of next-generation androgen receptor antagonists and targeted agents, supported by well-established payer systems that place a premium on clinical outcomes. Latin American markets exhibit slower uptake due to budgetary constraints, yet incremental improvements in reimbursement policies are broadening accessibility. Within Europe, the Middle East, and Africa, market heterogeneity is pronounced: Western European nations benefit from centralized pricing negotiations and value-based agreements, whereas emerging economies in Eastern Europe and the Middle East contend with infrastructure gaps that delay drug launches. In Africa, limited diagnostic capabilities further impact patient identification and treatment initiation. The Asia-Pacific region is characterized by rapid growth in China and India, where domestic biotech investment and regulatory acceleration are fostering earlier entry of novel mechanism agents. Japan and South Korea continue to lead in targeted therapy adoption, bolstered by advanced molecular diagnostics and favorable reimbursement pathways. Across all regions, tailored market strategies that address local regulatory environments, health-economic considerations, and patient access challenges are paramount for sustainable expansion.

Prominent Industry Players Driving Innovation and Competitive Positioning

A cadre of global biopharmaceutical leaders and innovative newcomers is shaping the competitive landscape for castration-resistant prostate cancer therapeutics. Established players such as AbbVie Inc. and Astellas Pharma Inc. have defined the market with androgen receptor antagonists, while AstraZeneca PLC and Bayer AG maintain momentum through Cyp17 inhibitor platforms. Merck & Co., Inc. and Bristol-Myers Squibb Company are advancing checkpoint inhibitors in combination settings, and Pfizer Inc. and Roche Holding AG are exploring targeted therapies and antibody-drug conjugates. Mid-sized firms including Amgen Inc., Novartis International AG, and Takeda Pharmaceutical Company Limited leverage extensive oncology experience to optimize clinical development pathways. At the same time, specialized companies such as Clovis Oncology, Inc. and BeiGene, Ltd. are moving PARP inhibitors and novel small molecules through late-stage trials. Biotech innovators like Arcus Biosciences, Inc., Array BioPharma Inc., and Exelixis, Inc. focus on early-stage immunomodulators and signal transduction disruptors, while entities such as Dendreon Pharmaceuticals, Inc. and Seattle Genetics, Inc. pursue cell-based therapies and antibody-drug conjugates. Collectively, this ecosystem balances late-stage commercialization expertise with cutting-edge research, driving a dynamic and competitive market environment.

Actionable Recommendations to Accelerate Growth and Optimize Clinical Impact

Industry leaders should prioritize strategic initiatives to capitalize on evolving market conditions and optimize patient impact. First, forging collaborative relationships with regulatory agencies can expedite approval pathways for innovative agents and secure early-access programs. Second, integrating biomarker-driven trial designs will enhance patient selection, improve response rates, and strengthen value propositions for payers. Third, establishing resilient supply chains-through nearshore manufacturing partnerships and diversified sourcing-will mitigate tariff-related cost pressures. Fourth, engaging proactively with payers to negotiate value-based agreements and demonstrate real-world effectiveness can facilitate favorable reimbursement. Fifth, adopting adaptive clinical trial methodologies will accelerate data generation and allow mid-course corrections, reducing time to market. Sixth, expanding presence in high-growth regions by tailoring market access strategies to local regulatory and economic landscapes will unlock new revenue streams. Seventh, leveraging digital health platforms for remote patient monitoring and adherence support will improve clinical outcomes and generate real-world evidence. Finally, embedding patient-centric endpoints and quality-of-life measures across development programs will differentiate products in a crowded therapeutic field and align with evolving stakeholder expectations.

Concluding Perspectives on the Evolving Prostate Cancer Drug Market

The castration-resistant prostate cancer treatment landscape stands at a pivotal juncture, defined by the convergence of scientific innovation, regulatory evolution, and shifting economic considerations. Novel therapeutic classes-ranging from immunomodulators to targeted small molecules-are reshaping treatment algorithms, while advanced biomarkers and digital health tools refine patient selection and outcome measurement. At the same time, policy measures such as the 2025 tariffs introduce new complexities that demand agile supply chain and pricing strategies. Regional heterogeneity underscores the importance of localized market approaches, and segmentation insights reveal pathways to optimize clinical development and commercial positioning. Within this dynamic context, companies that blend rigorous scientific rigor with proactive stakeholder engagement will emerge as market leaders. By aligning research priorities with payer expectations, regulatory requirements, and patient needs, stakeholders can deliver transformative therapies that extend survival and improve quality of life for patients with advanced disease. The insights presented here provide a roadmap to navigate the complexities of this evolving market and to seize opportunities for sustainable growth.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Therapeutic Mechanism
    • Androgen Receptor Antagonists
    • Cyp17 Inhibitors
    • Novel Mechanism Agents
      • Immunomodulators
      • Signal Transduction Disruptors
  • Drug Classification
    • Chemotherapy Agents
    • Hormonal Therapy Agents
    • Immunotherapy Agents
    • Targeted Therapy Agents
  • Clinical Development Stage
    • Approved and Marketed
    • Phase I Trials
    • Phase II Trials
    • Phase III Trials
      • Completed
      • Ongoing
    • Preclinical Testing
  • Administration Route
    • Intravenous
    • Oral
    • Subcutaneous
    • Transdermal
  • Safety and Efficacy
    • Adverse Effect Profile
      • Mild Reactions
      • Moderate Reactions
      • Severe Reactions
    • Drug Interaction Risks
    • Tolerance Levels
  • Patient Profile
    • Age Range
    • Comorbidities
    • Genetic Markers
    • Performance Status
  • Molecular and Chemical Structure
    • Biomarker Associations
    • Chemical Properties
    • Molecular Targets
    • Resistance Mechanisms
  • Market Adoption and Reimbursement
    • Adoption Rate
    • Cost Effectiveness
    • Insurance Coverage
    • Reimbursement Policies
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom
This research report delves into recent significant developments and analyzes trends in each of the following companies:
  • AbbVie Inc.
  • Allergan, Inc.
  • Amgen Inc.
  • Arcus Biosciences, Inc.
  • Array BioPharma Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bayer AG
  • BeiGene, Ltd.
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Clovis Oncology, Inc.
  • Dendreon Pharmaceuticals, Inc.
  • Eli Lilly and Company
  • Endo International plc
  • Exelixis, Inc.
  • Exicure, Inc.
  • Immunomedics, Inc.
  • Incyte Corporation
  • Janssen Pharmaceuticals, Inc.
  • Merck & Co., Inc.
  • Merrimack Pharmaceuticals, Inc.
  • Novartis International AG
  • Pfizer Inc.
  • Roche Holding AG
  • Sage Therapeutics, Inc.
  • Sanofi S.A.
  • Seattle Genetics, Inc.
  • Takeda Pharmaceutical Company Limited

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Castration-resistant Prostate Cancer Drugs Market, by Therapeutic Mechanism
8.1. Introduction
8.2. Androgen Receptor Antagonists
8.3. Cyp17 Inhibitors
8.4. Novel Mechanism Agents
8.4.1. Immunomodulators
8.4.2. Signal Transduction Disruptors
9. Castration-resistant Prostate Cancer Drugs Market, by Drug Classification
9.1. Introduction
9.2. Chemotherapy Agents
9.3. Hormonal Therapy Agents
9.4. Immunotherapy Agents
9.5. Targeted Therapy Agents
10. Castration-resistant Prostate Cancer Drugs Market, by Clinical Development Stage
10.1. Introduction
10.2. Approved And Marketed
10.3. Phase I Trials
10.4. Phase II Trials
10.5. Phase III Trials
10.5.1. Completed
10.5.2. Ongoing
10.6. Preclinical Testing
11. Castration-resistant Prostate Cancer Drugs Market, by Administration Route
11.1. Introduction
11.2. Intravenous
11.3. Oral
11.4. Subcutaneous
11.5. Transdermal
12. Castration-resistant Prostate Cancer Drugs Market, by Safety And Efficacy
12.1. Introduction
12.2. Adverse Effect Profile
12.2.1. Mild Reactions
12.2.2. Moderate Reactions
12.2.3. Severe Reactions
12.3. Drug Interaction Risks
12.4. Tolerance Levels
13. Castration-resistant Prostate Cancer Drugs Market, by Patient Profile
13.1. Introduction
13.2. Age Range
13.3. Comorbidities
13.4. Genetic Markers
13.5. Performance Status
14. Castration-resistant Prostate Cancer Drugs Market, by Molecular And Chemical Structure
14.1. Introduction
14.2. Biomarker Associations
14.3. Chemical Properties
14.4. Molecular Targets
14.5. Resistance Mechanisms
15. Castration-resistant Prostate Cancer Drugs Market, by Market Adoption And Reimbursement
15.1. Introduction
15.2. Adoption Rate
15.3. Cost Effectiveness
15.4. Insurance Coverage
15.5. Reimbursement Policies
16. Americas Castration-resistant Prostate Cancer Drugs Market
16.1. Introduction
16.2. Argentina
16.3. Brazil
16.4. Canada
16.5. Mexico
16.6. United States
17. Asia-Pacific Castration-resistant Prostate Cancer Drugs Market
17.1. Introduction
17.2. Australia
17.3. China
17.4. India
17.5. Indonesia
17.6. Japan
17.7. Malaysia
17.8. Philippines
17.9. Singapore
17.10. South Korea
17.11. Taiwan
17.12. Thailand
17.13. Vietnam
18. Europe, Middle East & Africa Castration-resistant Prostate Cancer Drugs Market
18.1. Introduction
18.2. Denmark
18.3. Egypt
18.4. Finland
18.5. France
18.6. Germany
18.7. Israel
18.8. Italy
18.9. Netherlands
18.10. Nigeria
18.11. Norway
18.12. Poland
18.13. Qatar
18.14. Russia
18.15. Saudi Arabia
18.16. South Africa
18.17. Spain
18.18. Sweden
18.19. Switzerland
18.20. Turkey
18.21. United Arab Emirates
18.22. United Kingdom
19. Competitive Landscape
19.1. Market Share Analysis, 2024
19.2. FPNV Positioning Matrix, 2024
19.3. Competitive Analysis
19.3.1. AbbVie Inc.
19.3.2. Allergan, Inc.
19.3.3. Amgen Inc.
19.3.4. Arcus Biosciences, Inc.
19.3.5. Array BioPharma Inc.
19.3.6. Astellas Pharma Inc.
19.3.7. AstraZeneca PLC
19.3.8. Bayer AG
19.3.9. BeiGene, Ltd.
19.3.10. Boehringer Ingelheim GmbH
19.3.11. Bristol-Myers Squibb Company
19.3.12. Celgene Corporation
19.3.13. Clovis Oncology, Inc.
19.3.14. Dendreon Pharmaceuticals, Inc.
19.3.15. Eli Lilly and Company
19.3.16. Endo International plc
19.3.17. Exelixis, Inc.
19.3.18. Exicure, Inc.
19.3.19. Immunomedics, Inc.
19.3.20. Incyte Corporation
19.3.21. Janssen Pharmaceuticals, Inc.
19.3.22. Merck & Co., Inc.
19.3.23. Merrimack Pharmaceuticals, Inc.
19.3.24. Novartis International AG
19.3.25. Pfizer Inc.
19.3.26. Roche Holding AG
19.3.27. Sage Therapeutics, Inc.
19.3.28. Sanofi S.A.
19.3.29. Seattle Genetics, Inc.
19.3.30. Takeda Pharmaceutical Company Limited
20. ResearchAI
21. ResearchStatistics
22. ResearchContacts
23. ResearchArticles
24. Appendix
List of Figures
FIGURE 1. CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET MULTI-CURRENCY
FIGURE 2. CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET MULTI-LANGUAGE
FIGURE 3. CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2024 VS 2030 (%)
FIGURE 8. GLOBAL CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY DRUG CLASSIFICATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY DRUG CLASSIFICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY CLINICAL DEVELOPMENT STAGE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY CLINICAL DEVELOPMENT STAGE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2030 (%)
FIGURE 14. GLOBAL CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY SAFETY AND EFFICACY, 2024 VS 2030 (%)
FIGURE 16. GLOBAL CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY SAFETY AND EFFICACY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY PATIENT PROFILE, 2024 VS 2030 (%)
FIGURE 18. GLOBAL CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY PATIENT PROFILE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. GLOBAL CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY MOLECULAR AND CHEMICAL STRUCTURE, 2024 VS 2030 (%)
FIGURE 20. GLOBAL CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY MOLECULAR AND CHEMICAL STRUCTURE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. GLOBAL CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY MARKET ADOPTION AND REIMBURSEMENT, 2024 VS 2030 (%)
FIGURE 22. GLOBAL CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY MARKET ADOPTION AND REIMBURSEMENT, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. AMERICAS CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. AMERICAS CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. UNITED STATES CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 26. UNITED STATES CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. ASIA-PACIFIC CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 28. ASIA-PACIFIC CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 29. EUROPE, MIDDLE EAST & AFRICA CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 30. EUROPE, MIDDLE EAST & AFRICA CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 31. CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 32. CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY ANDROGEN RECEPTOR ANTAGONISTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY CYP17 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY NOVEL MECHANISM AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY IMMUNOMODULATORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY SIGNAL TRANSDUCTION DISRUPTORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY NOVEL MECHANISM AGENTS, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY DRUG CLASSIFICATION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY HORMONAL THERAPY AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY CLINICAL DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY APPROVED AND MARKETED, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY PHASE I TRIALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY PHASE II TRIALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY PHASE III TRIALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY COMPLETED, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY ONGOING, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY PHASE III TRIALS, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY PRECLINICAL TESTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY SAFETY AND EFFICACY, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY ADVERSE EFFECT PROFILE, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY MILD REACTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY MODERATE REACTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY SEVERE REACTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY ADVERSE EFFECT PROFILE, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY DRUG INTERACTION RISKS, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY TOLERANCE LEVELS, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY PATIENT PROFILE, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY AGE RANGE, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY COMORBIDITIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY GENETIC MARKERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY PERFORMANCE STATUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY MOLECULAR AND CHEMICAL STRUCTURE, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY BIOMARKER ASSOCIATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY CHEMICAL PROPERTIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY MOLECULAR TARGETS, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY RESISTANCE MECHANISMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY MARKET ADOPTION AND REIMBURSEMENT, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY ADOPTION RATE, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY COST EFFECTIVENESS, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY INSURANCE COVERAGE, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY REIMBURSEMENT POLICIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. AMERICAS CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2018-2030 (USD MILLION)
TABLE 56. AMERICAS CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY NOVEL MECHANISM AGENTS, 2018-2030 (USD MILLION)
TABLE 57. AMERICAS CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY DRUG CLASSIFICATION, 2018-2030 (USD MILLION)
TABLE 58. AMERICAS CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY CLINICAL DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 59. AMERICAS CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY PHASE III TRIALS, 2018-2030 (USD MILLION)
TABLE 60. AMERICAS CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 61. AMERICAS CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY SAFETY AND EFFICACY, 2018-2030 (USD MILLION)
TABLE 62. AMERICAS CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY ADVERSE EFFECT PROFILE, 2018-2030 (USD MILLION)
TABLE 63. AMERICAS CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY PATIENT PROFILE, 2018-2030 (USD MILLION)
TABLE 64. AMERICAS CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY MOLECULAR AND CHEMICAL STRUCTURE, 2018-2030 (USD MILLION)
TABLE 65. AMERICAS CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY MARKET ADOPTION AND REIMBURSEMENT, 2018-2030 (USD MILLION)
TABLE 66. AMERICAS CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 67. ARGENTINA CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2018-2030 (USD MILLION)
TABLE 68. ARGENTINA CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY NOVEL MECHANISM AGENTS, 2018-2030 (USD MILLION)
TABLE 69. ARGENTINA CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY DRUG CLASSIFICATION, 2018-2030 (USD MILLION)
TABLE 70. ARGENTINA CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY CLINICAL DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 71. ARGENTINA CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY PHASE III TRIALS, 2018-2030 (USD MILLION)
TABLE 72. ARGENTINA CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 73. ARGENTINA CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY SAFETY AND EFFICACY, 2018-2030 (USD MILLION)
TABLE 74. ARGENTINA CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY ADVERSE EFFECT PROFILE, 2018-2030 (USD MILLION)
TABLE 75. ARGENTINA CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY PATIENT PROFILE, 2018-2030 (USD MILLION)
TABLE 76. ARGENTINA CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY MOLECULAR AND CHEMICAL STRUCTURE, 2018-2030 (USD MILLION)
TABLE 77. ARGENTINA CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY MARKET ADOPTION AND REIMBURSEMENT, 2018-2030 (USD MILLION)
TABLE 78. BRAZIL CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2018-2030 (USD MILLION)
TABLE 79. BRAZIL CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY NOVEL MECHANISM AGENTS, 2018-2030 (USD MILLION)
TABLE 80. BRAZIL CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY DRUG CLASSIFICATION, 2018-2030 (USD MILLION)
TABLE 81. BRAZIL CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY CLINICAL DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 82. BRAZIL CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY PHASE III TRIALS, 2018-2030 (USD MILLION)
TABLE 83. BRAZIL CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 84. BRAZIL CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY SAFETY AND EFFICACY, 2018-2030 (USD MILLION)
TABLE 85. BRAZIL CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY ADVERSE EFFECT PROFILE, 2018-2030 (USD MILLION)
TABLE 86. BRAZIL CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY PATIENT PROFILE, 2018-2030 (USD MILLION)
TABLE 87. BRAZIL CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY MOLECULAR AND CHEMICAL STRUCTURE, 2018-2030 (USD MILLION)
TABLE 88. BRAZIL CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY MARKET ADOPTION AND REIMBURSEMENT, 2018-2030 (USD MILLION)
TABLE 89. CANADA CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2018-2030 (USD MILLION)
TABLE 90. CANADA CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY NOVEL MECHANISM AGENTS, 2018-2030 (USD MILLION)
TABLE 91. CANADA CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY DRUG CLASSIFICATION, 2018-2030 (USD MILLION)
TABLE 92. CANADA CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY CLINICAL DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 93. CANADA CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY PHASE III TRIALS, 2018-2030 (USD MILLION)
TABLE 94. CANADA CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 95. CANADA CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY SAFETY AND EFFICACY, 2018-2030 (USD MILLION)
TABLE 96. CANADA CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY ADVERSE EFFECT PROFILE, 2018-2030 (USD MILLION)
TABLE 97. CANADA CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY PATIENT PROFILE, 2018-2030 (USD MILLION)
TABLE 98. CANADA CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY MOLECULAR AND CHEMICAL STRUCTURE, 2018-2030 (USD MILLION)
TABLE 99. CANADA CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY MARKET ADOPTION AND REIMBURSEMENT, 2018-2030 (USD MILLION)
TABLE 100. MEXICO CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2018-2030 (USD MILLION)
TABLE 101. MEXICO CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY NOVEL MECHANISM AGENTS, 2018-2030 (USD MILLION)
TABLE 102. MEXICO CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY DRUG CLASSIFICATION, 2018-2030 (USD MILLION)
TABLE 103. MEXICO CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY CLINICAL DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 104. MEXICO CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY PHASE III TRIALS, 2018-2030 (USD MILLION)
TABLE 105. MEXICO CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 106. MEXICO CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY SAFETY AND EFFICACY, 2018-2030 (USD MILLION)
TABLE 107. MEXICO CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY ADVERSE EFFECT PROFILE, 2018-2030 (USD MILLION)
TABLE 108. MEXICO CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY PATIENT PROFILE, 2018-2030 (USD MILLION)
TABLE 109. MEXICO CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY MOLECULAR AND CHEMICAL STRUCTURE, 2018-2030 (USD MILLION)
TABLE 110. MEXICO CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY MARKET ADOPTION AND REIMBURSEMENT, 2018-2030 (USD MILLION)
TABLE 111. UNITED STATES CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2018-2030 (USD MILLION)
TABLE 112. UNITED STATES CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY NOVEL MECHANISM AGENTS, 2018-2030 (USD MILLION)
TABLE 113. UNITED STATES CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY DRUG CLASSIFICATION, 2018-2030 (USD MILLION)
TABLE 114. UNITED STATES CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY CLINICAL DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 115. UNITED STATES CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY PHASE III TRIALS, 2018-2030 (USD MILLION)
TABLE 116. UNITED STATES CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 117. UNITED STATES CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY SAFETY AND EFFICACY, 2018-2030 (USD MILLION)
TABLE 118. UNITED STATES CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY ADVERSE EFFECT PROFILE, 2018-2030 (USD MILLION)
TABLE 119. UNITED STATES CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY PATIENT PROFILE, 2018-2030 (USD MILLION)
TABLE 120. UNITED STATES CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY MOLECULAR AND CHEMICAL STRUCTURE, 2018-2030 (USD MILLION)
TABLE 121. UNITED STATES CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY MARKET ADOPTION AND REIMBURSEMENT, 2018-2030 (USD MILLION)
TABLE 122. UNITED STATES CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 123. ASIA-PACIFIC CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2018-2030 (USD MILLION)
TABLE 124. ASIA-PACIFIC CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY NOVEL MECHANISM AGENTS, 2018-2030 (USD MILLION)
TABLE 125. ASIA-PACIFIC CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY DRUG CLASSIFICATION, 2018-2030 (USD MILLION)
TABLE 126. ASIA-PACIFIC CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY CLINICAL DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 127. ASIA-PACIFIC CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY PHASE III TRIALS, 2018-2030 (USD MILLION)
TABLE 128. ASIA-PACIFIC CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 129. ASIA-PACIFIC CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY SAFETY AND EFFICACY, 2018-2030 (USD MILLION)
TABLE 130. ASIA-PACIFIC CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY ADVERSE EFFECT PROFILE, 2018-2030 (USD MILLION)
TABLE 131. ASIA-PACIFIC CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY PATIENT PROFILE, 2018-2030 (USD MILLION)
TABLE 132. ASIA-PACIFIC CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY MOLECULAR AND CHEMICAL STRUCTURE, 2018-2030 (USD MILLION)
TABLE 133. ASIA-PACIFIC CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY MARKET ADOPTION AND REIMBURSEMENT, 2018-2030 (USD MILLION)
TABLE 134. ASIA-PACIFIC CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 135. AUSTRALIA CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2018-2030 (USD MILLION)
TABLE 136. AUSTRALIA CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY NOVEL MECHANISM AGENTS, 2018-2030 (USD MILLION)
TABLE 137. AUSTRALIA CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY DRUG CLASSIFICATION, 2018-2030 (USD MILLION)
TABLE 138. AUSTRALIA CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY CLINICAL DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 139. AUSTRALIA CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY PHASE III TRIALS, 2018-2030 (USD MILLION)
TABLE 140. AUSTRALIA CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 141. AUSTRALIA CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY SAFETY AND EFFICACY, 2018-2030 (USD MILLION)
TABLE 142. AUSTRALIA CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY ADVERSE EFFECT PROFILE, 2018-2030 (USD MILLION)
TABLE 143. AUSTRALIA CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY PATIENT PROFILE, 2018-2030 (USD MILLION)
TABLE 144. AUSTRALIA CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY MOLECULAR AND CHEMICAL STRUCTURE, 2018-2030 (USD MILLION)
TABLE 145. AUSTRALIA CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY MARKET ADOPTION AND REIMBURSEMENT, 2018-2030 (USD MILLION)
TABLE 146. CHINA CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2018-2030 (USD MILLION)
TABLE 147. CHINA CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY NOVEL MECHANISM AGENTS, 2018-2030 (USD MILLION)
TABLE 148. CHINA CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY DRUG CLASSIFICATION, 2018-2030 (USD MILLION)
TABLE 149. CHINA CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY CLINICAL DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 150. CHINA CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY PHASE III TRIALS, 2018-2030 (USD MILLION)
TABLE 151. CHINA CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 152. CHINA CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY SAFETY AND EFFICACY, 2018-2030 (USD MILLION)
TABLE 153. CHINA CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY ADVERSE EFFECT PROFILE, 2018-2030 (USD MILLION)
TABLE 154. CHINA CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY PATIENT PROFILE, 2018-2030 (USD MILLION)
TABLE 155. CHINA CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY MOLECULAR AND CHEMICAL STRUCTURE, 2018-2030 (USD MILLION)
TABLE 156. CHINA CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY MARKET ADOPTION AND REIMBURSEMENT, 2018-2030 (USD MILLION)
TABLE 157. INDIA CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2018-2030 (USD MILLION)
TABLE 158. INDIA CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY NOVEL MECHANISM AGENTS, 2018-2030 (USD MILLION)
TABLE 159. INDIA CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY DRUG CLASSIFICATION, 2018-2030 (USD MILLION)
TABLE 160. INDIA CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY CLINICAL DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 161. INDIA CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY PHASE III TRIALS, 2018-2030 (USD MILLION)
TABLE 162. INDIA CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 163. INDIA CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY SAFETY AND EFFICACY, 2018-2030 (USD MILLION)
TABLE 164. INDIA CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY ADVERSE EFFECT PROFILE, 2018-2030 (USD MILLION)
TABLE 165. INDIA CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY PATIENT PROFILE, 2018-2030 (USD MILLION)
TABLE 166. INDIA CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY MOLECULAR AND CHEMICAL STRUCTURE, 2018-2030 (USD MILLION)
TABLE 167. INDIA CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY MARKET ADOPTION AND REIMBURSEMENT, 2018-2030 (USD MILLION)
TABLE 168. INDONESIA CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2018-2030 (USD MILLION)
TABLE 169. INDONESIA CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY NOVEL MECHANISM AGENTS, 2018-2030 (USD MILLION)
TABLE 170. INDONESIA CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY DRUG CLASSIFICATION, 2018-2030 (USD MILLION)
TABLE 171. INDONESIA CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY CLINICAL DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 172. INDONESIA CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY PHASE III TRIALS, 2018-2030 (USD MILLION)
TABLE 173. INDONESIA CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 174. INDONESIA CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY SAFETY AND EFFICACY, 2018-2030 (USD MILLION)
TABLE 175. INDONESIA CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY ADVERSE EFFECT PROFILE, 2018-2030 (USD MILLION)
TABLE 176. INDONESIA CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY PATIENT PROFILE, 2018-2030 (USD MILLION)
TABLE 177. INDONESIA CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY MOLECULAR AND CHEMICAL STRUCTURE, 2018-2030 (USD MILLION)
TABLE 178. INDONESIA CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY MARKET ADOPTION AND REIMBURSEMENT, 2018-2030 (USD MILLION)
TABLE 179. JAPAN CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2018-2030 (USD MILLION)
TABLE 180. JAPAN CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY NOVEL MECHANISM AGENTS, 2018-2030 (USD MILLION)
TABLE 181. JAPAN CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY DRUG CLASSIFICATION, 2018-2030 (USD MILLION)
TABLE 182. JAPAN CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY CLINICAL DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 183. JAPAN CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY PHASE III TRIALS, 2018-2030 (USD MILLION)
TABLE 184. JAPAN CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 185. JAPAN CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY SAFETY AND EFFICACY, 2018-2030 (USD MILLION)
TABLE 186. JAPAN CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY ADVERSE EFFECT PROFILE, 2018-2030 (USD MILLION)
TABLE 187. JAPAN CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY PATIENT PROFILE, 2018-2030 (USD MILLION)
TABLE 188. JAPAN CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY MOLECULAR AND CHEMICAL STRUCTURE, 2018-2030 (USD MILLION)
TABLE 189. JAPAN CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY MARKET ADOPTION AND REIMBURSEMENT, 2018-2030 (USD MILLION)
TABLE 190. MALAYSIA CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2018-2030 (USD MILLION)
TABLE 191. MALAYSIA CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY NOVEL MECHANISM AGENTS, 2018-2030 (USD MILLION)
TABLE 192. MALAYSIA CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY DRUG CLASSIFICATION, 2018-2030 (USD MILLION)
TABLE 193. MALAYSIA CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY CLINICAL DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 194. MALAYSIA CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY PHASE III TRIALS, 2018-2030 (USD MILLION)
TABLE 195. MALAYSIA CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 196. MALAYSIA CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY SAFETY AND EFFICACY, 2018-2030 (USD MILLION)
TABLE 197. MALAYSIA CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY ADVERSE EFFECT PROFILE, 2018-2030 (USD MILLION)
TABLE 198. MALAYSIA CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY PATIENT PROFILE, 2018-2030 (USD MILLION)
TABLE 199. MALAYSIA CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY MOLECULAR AND CHEMICAL STRUCTURE, 2018-2030 (USD MILLION)
TABLE 200. MALAYSIA CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY MARKET ADOPTION AND REIMBURSEMENT, 2018-2030 (USD MILLION)
TABLE 201. PHILIPPINES CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2018-2030 (USD MILLION)
TABLE 202. PHILIPPINES CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY NOVEL MECHANISM AGENTS, 2018-2030 (USD MILLION)
TABLE 203. PHILIPPINES CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY DRUG CLASSIFICATION, 2018-2030 (USD MILLION)
TABLE 204. PHILIPPINES CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY CLINICAL DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 205. PHILIPPINES CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY PHASE III TRIALS, 2018-2030 (USD MILLION)
TABLE 206. PHILIPPINES CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 207. PHILIPPINES CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY SAFETY AND EFFICACY, 2018-2030 (USD MILLION)
TABLE 208. PHILIPPINES CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY ADVERSE EFFECT PROFILE, 2018-2030 (USD MILLION)
TABLE 209. PHILIPPINES CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY PATIENT PROFILE, 2018-2030 (USD MILLION)
TABLE 210. PHILIPPINES CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY MOLECULAR AND CHEMICAL STRUCTURE, 2018-2030 (USD MILLION)
TABLE 211. PHILIPPINES CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY MARKET ADOPTION AND REIMBURSEMENT, 2018-2030 (USD MILLION)
TABLE 212. SINGAPORE CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2018-2030 (USD MILLION)
TABLE 213. SINGAPORE CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY NOVEL MECHANISM AGENTS, 2018-2030 (USD MILLION)
TABLE 214. SINGAPORE CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY DRUG CLASSIFICATION, 2018-2030 (USD MILLION)
TABLE 215. SINGAPORE CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY CLINICAL DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 216. SINGAPORE CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY PHASE III TRIALS, 2018-2030 (USD MILLION)
TABLE 217. SINGAPORE CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 218. SINGAPORE CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY SAFETY AND EFFICACY, 2018-2030 (USD MILLION)
TABLE 219. SINGAPORE CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY ADVERSE EFFECT PROFILE, 2018-2030 (USD MILLION)
TABLE 220. SINGAPORE CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY PATIENT PROFILE, 2018-2030 (USD MILLION)
TABLE 221. SINGAPORE CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY MOLECULAR AND CHEMICAL STRUCTURE, 2018-2030 (USD MILLION)
TABLE 222. SINGAPORE CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY MARKET ADOPTION AND REIMBURSEMENT, 2018-2030 (USD MILLION)
TABLE 223. SOUTH KOREA CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2018-2030 (USD MILLION)
TABLE 224. SOUTH KOREA CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY NOVEL MECHANISM AGENTS, 2018-2030 (USD MILLION)
TABLE 225. SOUTH KOREA CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY DRUG CLASSIFICATION, 2018-2030 (USD MILLION)
TABLE 226. SOUTH KOREA CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY CLINICAL DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 227. SOUTH KOREA CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY PHASE III TRIALS, 2018-2030 (USD MILLION)
TABLE 228. SOUTH KOREA CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 229. SOUTH KOREA CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY SAFETY AND EFFICACY, 2018-2030 (USD MILLION)
TABLE 230. SOUTH KOREA CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY ADVERSE EFFECT PROFILE, 2018-2030 (USD MILLION)
TABLE 231. SOUTH KOREA CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY PATIENT PROFILE, 2018-2030 (USD MILLION)
TABLE 232. SOUTH KOREA CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY MOLECULAR AND CHEMICAL STRUCTURE, 2018-2030 (USD MILLION)
TABLE 233. SOUTH KOREA CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY MARKET ADOPTION AND REIMBURSEMENT, 2018-2030 (USD MILLION)
TABLE 234. TAIWAN CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2018-2030 (USD MILLION)
TABLE 235. TAIWAN CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY NOVEL MECHANISM AGENTS, 2018-2030 (USD MILLION)
TABLE 236. TAIWAN CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY DRUG CLASSIFICATION, 2018-2030 (USD MILLION)
TABLE 237. TAIWAN CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY CLINICAL DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 238. TAIWAN CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY PHASE III TRIALS, 2018-2030 (USD MILLION)
TABLE 239. TAIWAN CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 240. TAIWAN CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY SAFETY AND EFFICACY, 2018-2030 (USD MILLION)
TABLE 241. TAIWAN CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY ADVERSE EFFECT PROFILE, 2018-2030 (USD MILLION)
TABLE 242. TAIWAN CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY PATIENT PROFILE, 2018-2030 (USD MILLION)
TABLE 243. TAIWAN CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY MOLECULAR AND CHEMICAL STRUCTURE, 2018-2030 (USD MILLION)
TABLE 244. TAIWAN CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY MARKET ADOPTION AND REIMBURSEMENT, 2018-2030 (USD MILLION)
TABLE 245. THAILAND CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2018-2030 (USD MILLION)
TABLE 246. THAILAND CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY NOVEL MECHANISM AGENTS, 2018-2030 (USD MILLION)
TABLE 247. THAILAND CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY DRUG CLASSIFICATION, 2018-2030 (USD MILLION)
TABLE 248. THAILAND CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY CLINICAL DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 249. THAILAND CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY PHASE III TRIALS, 2018-2030 (USD MILLION)
TABLE 250. THAILAND CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 251. THAILAND CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY SAFETY AND EFFICACY, 2018-2030 (USD MILLION)
TABLE 252. THAILAND CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY ADVERSE EFFECT PROFILE, 2018-2030 (USD MILLION)
TABLE 253. THAILAND CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY PATIENT PROFILE, 2018-2030 (USD MILLION)
TABLE 254. THAILAND CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY MOLECULAR AND CHEMICAL STRUCTURE, 2018-2030 (USD MILLION)
TABLE 255. THAILAND CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY MARKET ADOPTION AND REIMBURSEMENT, 2018-2030 (USD MILLION)
TABLE 256. VIETNAM CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2018-2030 (USD MILLION)
TABLE 257. VIETNAM CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY NOVEL MECHANISM AGENTS, 2018-2030 (USD MILLION)
TABLE 258. VIETNAM CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY DRUG CLASSIFICATION, 2018-2030 (USD MILLION)
TABLE 259. VIETNAM CASTRATION-RESISTANT PROSTATE CANCER DRUGS MARKET SIZE, BY CLINICAL DEVELOPMENT STAGE, 2018-2030

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Castration-resistant Prostate Cancer Drugs market report include:
  • AbbVie Inc.
  • Allergan, Inc.
  • Amgen Inc.
  • Arcus Biosciences, Inc.
  • Array BioPharma Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bayer AG
  • BeiGene, Ltd.
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Clovis Oncology, Inc.
  • Dendreon Pharmaceuticals, Inc.
  • Eli Lilly and Company
  • Endo International plc
  • Exelixis, Inc.
  • Exicure, Inc.
  • Immunomedics, Inc.
  • Incyte Corporation
  • Janssen Pharmaceuticals, Inc.
  • Merck & Co., Inc.
  • Merrimack Pharmaceuticals, Inc.
  • Novartis International AG
  • Pfizer Inc.
  • Roche Holding AG
  • Sage Therapeutics, Inc.
  • Sanofi S.A.
  • Seattle Genetics, Inc.
  • Takeda Pharmaceutical Company Limited

Related Topics

Related Reports

Metastatic Castration-Resistant Prostate Cancer Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034 - Product Image

Metastatic Castration-Resistant Prostate Cancer Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

  • Report
  • 138 Pages
  • Global
From
Metastatic Castration Resistant Prostate Cancer Market - Product Image

Metastatic Castration Resistant Prostate Cancer Market

  • Report
  • 250 Pages
  • Global
From
Metastatic Castration-Resistant Prostate Cancer- Pipeline Insight, 2025 - Product Image

Metastatic Castration-Resistant Prostate Cancer- Pipeline Insight, 2025

  • Clinical Trials
  • 240 Pages
  • Global
From
Castration-resistant Prostate Cancer Treatment Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2030 - Product Image

Castration-resistant Prostate Cancer Treatment Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2030

  • Report
  • 180 Pages
  • Global
From
Castration-resistant Prostate Cancer Drug Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Castration-resistant Prostate Cancer Drug Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.